The Food and Drug Administration has approved the first influenza vaccine built on messenger RNA technology, the same platform that powered the leading COVID-19 shots. The vaccine, branded mFLUSIVA, is cleared for adults aged 50 and older ahead of the 2026 to 2027 respiratory virus season.
The approval marks a milestone for a class of vaccines that proved its speed during the pandemic and is now being turned toward seasonal flu. Manufacturers have long argued that mRNA could make flu vaccines faster to update and better matched to circulating strains.
What mFLUSIVA is and how the platform works
The product, developed by Moderna and known in trials as mRNA-1010, delivers genetic instructions that prompt a person’s cells to produce a harmless piece of the influenza virus, training the immune system to recognize the real pathogen. Traditional flu shots are made by growing virus in eggs or cell cultures, a slower process that can lag behind fast-changing strains. Because mRNA vaccines are synthesized chemically, they can in principle be redesigned and manufactured more quickly, a potential advantage when the dominant flu strain shifts from year to year. The approval details were tracked in industry coverage aggregated by Drugs.com.
Who is eligible under the clearance
The vaccine is authorized for adults 50 and older, a population that bears a disproportionate share of severe flu illness and hospitalization each winter. Full approval covers adults aged 50 to 64 based on a large phase 3 trial, while coverage for those 65 and older was granted through accelerated approval supported by an immunogenicity study, with a confirmatory trial required afterward. That tiered structure reflects the different bodies of evidence available for each age band at the time of the decision.
Older adults are a logical first target for the technology. Influenza sends hundreds of thousands of people to the hospital in a bad season, and the burden falls heaviest on those over 65, whose aging immune systems respond less robustly to conventional shots. High-dose and adjuvanted vaccines were developed precisely to address that gap, and an mRNA option adds another tool aimed at the same vulnerable group. Focusing the initial approval on adults 50 and older concentrates the vaccine where the potential public health payoff is largest while additional data are gathered.
The efficacy seen in testing
In the pivotal study, laboratory-confirmed influenza-like illness occurred in 2.0 percent of people who received mFLUSIVA compared with 2.8 percent of those given a standard-dose comparator flu vaccine. That difference corresponds to a relative vaccine efficacy of about 26.6 percent, meaning the mRNA shot cut cases by roughly a quarter relative to an existing vaccine rather than relative to no vaccine at all. The large trial that anchored the approval, testing the vaccine in adults 50 and older, is registered on the federal clinical trials database as study NCT05566639.
Why relative efficacy is the key number
The efficacy figure describes an improvement over a currently used vaccine, not protection compared with an unvaccinated state. That framing is important because flu vaccines are typically judged against the best available option once a standard of care already exists. A vaccine that outperforms today’s shots by a measurable margin can translate into fewer infections across a large population, even if the percentage sounds modest. For older adults, whose immune systems respond less vigorously, incremental gains in protection carry real weight.
What the approval means for the coming flu season
Moderna has said it expects the vaccine to be available in the weeks following approval, in time for the 2026 to 2027 respiratory virus season. Its arrival gives older adults a new choice alongside established egg-based and cell-based flu shots. Whether it becomes a preferred option will depend on real-world uptake, guidance from immunization advisers, and how the vaccine performs against the strains that actually circulate this winter.
A broader shift toward mRNA respiratory vaccines
Beyond this single product, the approval signals that mRNA is expanding from COVID-19 into the wider field of respiratory disease. Vaccine developers are pursuing mRNA formulations against several pathogens and even combination shots that could target flu and COVID-19 together. The clearance of a seasonal influenza vaccine on this platform is an early proof point for that strategy, and its performance this season will help shape how quickly the technology moves into routine flu prevention for the general public.
One long-standing frustration with flu vaccines is the lag built into their production. Manufacturers must predict months ahead which strains will dominate, then grow the virus in a slow process, and a mismatch between the forecast and the strains that actually circulate can blunt effectiveness. Because mRNA can be reprogrammed rapidly, proponents hope it will eventually allow formulations to be updated closer to the season, narrowing that window. Whether the platform delivers on that promise for influenza specifically will become clearer as real-world results accumulate over successive winters.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
